{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:10:32Z","timestamp":1794557432958,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Taxol and Abraxane, the US Food and Drug Administration-approved paclitaxel (PTX) formulations, have revealed hypersensitivity due to excipients and mediocre efficacy due to insufficient tumor penetration, respectively. Here we developed a sphingolipid-derived PTX nanovesicle (paclitaxome) via covalently conjugating PTX to sphingomyelin, which improved pharmacokinetics and enhanced efficacy in metastatic triple-negative breast cancer and pancreatic cancer female mice and reduced myelosuppression. To bolster tumor penetration and reduce phagocytosis, we engineered a cationization-enabled transcytosis machinery by installing an ultra-pH-sensitive azepane (AZE) probe into paclitaxome and masked nanovesicle surface with a CD47 \u2018self\u2019 peptide (CD47p). The resulting CD47p\/AZE\u2013paclitaxome synchronized the co-delivery of gemcitabine or carboplatin to boost tumor inhibition and eradicate metastasis in late-stage KPC-Luc pancreatic cancer model and prevent tumor relapse and extend survival in postsurgical 4T1-Luc2 triple-negative breast cancer model in female mice. CD47p\/AZE\u2013paclitaxome also outperformed previous promising PTX nanoformulations. Finally, the series of nanoparticle modifications was applied to camptothecin, demonstrating its generalizability.<\/jats:p>","DOI":"10.1038\/s43018-025-01029-7","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T09:03:25Z","timestamp":1755767005000},"page":"1734-1753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2016-0517","authenticated-orcid":false,"given":"Zhiren","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8546-7384","authenticated-orcid":false,"given":"Wenpan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2403-0601","authenticated-orcid":false,"given":"Yanhao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9029-1379","authenticated-orcid":false,"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen Ba","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3992-7157","authenticated-orcid":false,"given":"Leyla Estrella","family":"Cordova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron James","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-0402","authenticated-orcid":false,"given":"Jennifer","family":"Erdrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1277-5172","authenticated-orcid":false,"given":"Joyce","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavani","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5877-619X","authenticated-orcid":false,"given":"Jianqin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"1029_CR1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/07357909509031919","volume":"13","author":"MT Huizing","year":"1995","unstructured":"Huizing, M. T. et al. Taxanes: a new class of antitumor agents. Cancer Invest. 13, 381\u2013404 (1995).","journal-title":"Cancer Invest."},{"key":"1029_CR2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/annonc\/mdj100","volume":"17","author":"KL Hennenfent","year":"2006","unstructured":"Hennenfent, K. L. & Govindan, R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol. 17, 735\u2013749 (2006).","journal-title":"Ann. Oncol."},{"key":"1029_CR3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.addr.2017.02.003","volume":"122","author":"AM Sofias","year":"2017","unstructured":"Sofias, A. M., Dunne, M., Storm, G. & Allen, C. The battle of \u201cnano\u201d paclitaxel. Adv. Drug Delivery Rev. 122, 20\u201330 (2017).","journal-title":"Adv. Drug Delivery Rev."},{"key":"1029_CR4","first-page":"1000164","volume":"4","author":"P Ma","year":"2013","unstructured":"Ma, P. & Mumper, R. J. Paclitaxel nano-delivery systems: a comprehensive review. J. Nanomed. Nanotechnol. 4, 1000164 (2013).","journal-title":"J. Nanomed. Nanotechnol."},{"key":"1029_CR5","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.1016\/j.biomaterials.2014.04.108","volume":"35","author":"P Zhang","year":"2014","unstructured":"Zhang, P. et al. A PEG-Fmoc conjugate as a nanocarrier for paclitaxel. Biomaterials 35, 7146\u20137156 (2014).","journal-title":"Biomaterials"},{"key":"1029_CR6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4168\/aair.2016.8.2.174","volume":"8","author":"YN Kim","year":"2016","unstructured":"Kim, Y. N. et al. The hidden culprit: a case of repeated anaphylaxis to cremophor. Allergy Asthma Immunol. Res. 8, 174\u2013177 (2016).","journal-title":"Allergy Asthma Immunol. Res."},{"key":"1029_CR7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jnci\/90.4.300","volume":"90","author":"J Szebeni","year":"1998","unstructured":"Szebeni, J., Muggia, F. M. & Alving, C. R. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl. Cancer Inst. 90, 300\u2013306 (1998).","journal-title":"J. Natl. Cancer Inst."},{"key":"1029_CR8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/jnci\/85.8.676","volume":"85","author":"A Martoni","year":"1993","unstructured":"Martoni, A., Zamagni, C., Gheka, A. & Pannuti, F. Antihistamines in the treatment of taxol-induced paroxystic pain syndrome. J. Natl. Cancer Inst. 85, 676 (1993).","journal-title":"J. Natl. Cancer Inst."},{"key":"1029_CR9","first-page":"1991","volume":"20","author":"MJ Berger","year":"2012","unstructured":"Berger, M. J. et al. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support. Care. Cancer 20, 1991\u20131997 (2012).","journal-title":"Support. Care. Cancer"},{"key":"1029_CR10","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41565-021-00897-1","volume":"16","author":"R Li","year":"2021","unstructured":"Li, R. et al. Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. Nat. Nanotechnol. 16, 830\u2013839 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"1029_CR11","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms8939","volume":"6","author":"J Bhattacharyya","year":"2015","unstructured":"Bhattacharyya, J. et al. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models. Nat. Commun. 6, 7939 (2015).","journal-title":"Nat. Commun."},{"key":"1029_CR12","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387\u20136392 (1986).","journal-title":"Cancer Res."},{"key":"1029_CR13","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0002-9440(10)65006-7","volume":"156","author":"H Hashizume","year":"2000","unstructured":"Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363\u20131380 (2000).","journal-title":"Am. J. Pathol."},{"key":"1029_CR14","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"PA Oldenborg","year":"2000","unstructured":"Oldenborg, P. A. et al. Role of CD47 as a marker of self on red blood cells. Science 288, 2051\u20132054 (2000).","journal-title":"Science"},{"key":"1029_CR15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1229568","volume":"339","author":"PL Rodriguez","year":"2013","unstructured":"Rodriguez, P. L. et al. Minimal \u201cSelf\u201d peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971\u2013975 (2013).","journal-title":"Science"},{"key":"1029_CR16","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498\u2013503 (2017).","journal-title":"Nature"},{"key":"1029_CR17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/jpp\/rgaa005","volume":"73","author":"SM Gheibihayat","year":"2021","unstructured":"Gheibihayat, S. M., Jaafari, M. R., Hatamipour, M. & Sahebkar, A. Improvement of the pharmacokinetic characteristics of liposomal doxorubicin using CD47 biomimickry. J. Pharm. Pharmacol. 73, 169\u2013177 (2021).","journal-title":"J. Pharm. Pharmacol."},{"key":"1029_CR18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00280-009-1099-1","volume":"65","author":"Z Feng","year":"2010","unstructured":"Feng, Z., Zhao, G., Yu, L., Gough, D. & Howell, S. B. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother. Pharmacol. 65, 923\u2013930 (2010).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1029_CR19","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.7150\/jca.29898","volume":"10","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. J. Cancer 10, 4420\u20134429 (2019).","journal-title":"J. Cancer"},{"key":"1029_CR20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","volume":"5","author":"PA Philip","year":"2020","unstructured":"Philip, P. A. et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol. Hepatol. 5, 285\u2013294 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1029_CR21","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1029_CR22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clbc.2014.02.005","volume":"14","author":"E Mrozek","year":"2014","unstructured":"Mrozek, E. et al. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer. Clin. Breast. Cancer. 14, 228\u2013234 (2014).","journal-title":"Clin. Breast. Cancer."},{"key":"1029_CR23","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdq041","volume":"21","author":"XS Chen","year":"2010","unstructured":"Chen, X. S. et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann. Oncol. 21, 961\u2013967 (2010).","journal-title":"Ann. Oncol."},{"key":"1029_CR24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1158\/1078-0432.CCR-20-3646","volume":"27","author":"P Sharma","year":"2021","unstructured":"Sharma, P. et al. Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP). Clin. Cancer Res. 27, 975\u2013982 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1029_CR25","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/annonc\/mdy201","volume":"29","author":"DA Yardley","year":"2018","unstructured":"Yardley, D. A. et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann. Oncol. 29, 1763\u20131770 (2018).","journal-title":"Ann. Oncol."},{"key":"1029_CR26","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41565-021-00950-z","volume":"16","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. Nat. Nanotechnol. 16, 1130\u20131140 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"1029_CR27","doi-asserted-by":"publisher","unstructured":"Wang, Z. et al. The synthesis of sphingomyelin-derived paclitaxel protocol. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.6qpvrqjnblmk\/v1 (2025).","DOI":"10.17504\/protocols.io.6qpvrqjnblmk\/v1"},{"key":"1029_CR28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41565-019-0485-z","volume":"14","author":"Q Zhou","year":"2019","unstructured":"Zhou, Q. et al. Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy. Nat. Nanotechnol. 14, 799\u2013809 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"1029_CR29","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2017.52","volume":"12","author":"M Luo","year":"2017","unstructured":"Luo, M. et al. A STING-activating nanovaccine for cancer immunotherapy. Nat. Nanotechnol. 12, 648\u2013654 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"1029_CR30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1242\/jcs.00327","volume":"116","author":"PU Le","year":"2003","unstructured":"Le, P. U. & Nabi, I. R. Distinct caveolae-mediated endocytic pathways target the Golgi apparatus and the endoplasmic reticulum. J. Cell Sci. 116, 1059\u20131071 (2003).","journal-title":"J. Cell Sci."},{"key":"1029_CR31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/35074539","volume":"3","author":"L Pelkmans","year":"2001","unstructured":"Pelkmans, L., Kartenbeck, J. & Helenius, A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat. Cell Biol. 3, 473\u2013483 (2001).","journal-title":"Nat. Cell Biol."},{"key":"1029_CR32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1126\/science.1069784","volume":"296","author":"L Pelkmans","year":"2002","unstructured":"Pelkmans, L., Puntener, D. & Helenius, A. Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science 296, 535\u2013539 (2002).","journal-title":"Science"},{"key":"1029_CR33","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.0631766100","volume":"100","author":"Y Feng","year":"2003","unstructured":"Feng, Y. et al. Exo1: a new chemical inhibitor of the exocytic pathway. Proc. Natl Acad. Sci. USA 100, 6469\u20136474 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1029_CR34","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2004-5-3-214","volume":"5","author":"TM Williams","year":"2004","unstructured":"Williams, T. M. & Lisanti, M. P. The caveolin proteins. Genome Biol. 5, 214 (2004).","journal-title":"Genome Biol."},{"key":"1029_CR35","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","volume":"2","author":"KK Frese","year":"2012","unstructured":"Frese, K. K. et al. Nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2, 260\u2013269 (2012).","journal-title":"Cancer Discov."},{"key":"1029_CR36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18389-6","volume":"11","author":"A Muller-Deku","year":"2020","unstructured":"Muller-Deku, A. et al. Photoswitchable paclitaxel-based microtubule stabilisers allow optical control over the microtubule cytoskeleton. Nat. Commun. 11, 4640 (2020).","journal-title":"Nat. Commun."},{"key":"1029_CR37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejps.2017.03.003","volume":"103","author":"HM Kieler-Ferguson","year":"2017","unstructured":"Kieler-Ferguson, H. M. et al. Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids. Eur. J. Pharm. Sci. 103, 85\u201393 (2017).","journal-title":"Eur. J. Pharm. Sci."},{"key":"1029_CR38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3109\/1354750X.2012.715672","volume":"17","author":"MP Gamcsik","year":"2012","unstructured":"Gamcsik, M. P., Kasibhatla, M. S., Teeter, S. D. & Colvin, O. M. Glutathione levels in human tumors. Biomarkers 17, 671\u2013691 (2012).","journal-title":"Biomarkers"},{"key":"1029_CR39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nnano.2015.342","volume":"11","author":"Y Matsumoto","year":"2016","unstructured":"Matsumoto, Y. et al. Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat. Nanotechnol. 11, 533\u2013538 (2016).","journal-title":"Nat. Nanotechnol."},{"key":"1029_CR40","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1021\/acs.chemrev.7b00013","volume":"117","author":"M Srinivasarao","year":"2017","unstructured":"Srinivasarao, M. & Low, P. S. Ligand-targeted drug delivery. Chem. Rev. 117, 12133\u201312164 (2017).","journal-title":"Chem. Rev."},{"key":"1029_CR41","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","volume":"2","author":"TM Allen","year":"2002","unstructured":"Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750\u2013763 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"1029_CR42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17, 20\u201337 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1029_CR43","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1073\/pnas.1018382108","volume":"108","author":"C Wong","year":"2011","unstructured":"Wong, C. et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl Acad. Sci. USA 108, 2426\u20132431 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1029_CR44","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3109\/09687688.2010.521200","volume":"27","author":"B Yu","year":"2010","unstructured":"Yu, B., Tai, H. C., Xue, W., Lee, L. J. & Lee, R. J. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol. Membr. Biol. 27, 286\u2013298 (2010).","journal-title":"Mol. Membr. Biol."},{"key":"1029_CR45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk, J. S., Xu, Q., Kim, N., Hanes, J. & Ensign, L. M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99, 28\u201351 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1029_CR46","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/jphp.13098","volume":"71","author":"MF Attia","year":"2019","unstructured":"Attia, M. F., Anton, N., Wallyn, J., Omran, Z. & Vandamme, T. F. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J. Pharm. Pharmacol. 71, 1185\u20131198 (2019).","journal-title":"J. Pharm. Pharmacol."},{"key":"1029_CR47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbrc.2017.09.065","volume":"493","author":"S Syvanen","year":"2017","unstructured":"Syvanen, S., Eden, D. & Sehlin, D. Cationization increases brain distribution of an amyloid-beta protofibril selective F(ab\u2019)2 fragment. Biochem. Biophys. Res. Commun. 493, 120\u2013125 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1029_CR48","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","volume":"14","author":"A Akinc","year":"2019","unstructured":"Akinc, A. et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14, 1084\u20131087 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"1029_CR49","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s13346-018-0587-4","volume":"9","author":"M Sedighi","year":"2019","unstructured":"Sedighi, M. et al. Rapid optimization of liposome characteristics using a combined microfluidics and design-of-experiment approach. Drug Deliv. Transl. Res. 9, 404\u2013413 (2019).","journal-title":"Drug Deliv. Transl. Res."},{"key":"1029_CR50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nmat3819","volume":"13","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat. Mater. 13, 204\u2013212 (2014).","journal-title":"Nat. Mater."},{"key":"1029_CR51","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41565-022-01085-5","volume":"17","author":"M Liu","year":"2022","unstructured":"Liu, M. et al. A transistor-like pH-sensitive nanodetergent for selective cancer therapy. Nat. Nanotechnol. 17, 541\u2013551 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"1029_CR52","doi-asserted-by":"crossref","first-page":"17560","DOI":"10.1021\/ja207150n","volume":"133","author":"JZ Du","year":"2011","unstructured":"Du, J. Z., Du, X. J., Mao, C. Q. & Wang, J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J. Am. Chem. Soc. 133, 17560\u201317563 (2011).","journal-title":"J. Am. Chem. Soc."},{"key":"1029_CR53","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J. Clin. Oncol. 29, 4548\u20134554 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1029_CR54","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1093\/carcin\/bgt227","volume":"34","author":"N Awasthi","year":"2013","unstructured":"Awasthi, N. et al. Comparative benefits of nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Carcinogenesis 34, 2361\u20132369 (2013).","journal-title":"Carcinogenesis"},{"key":"1029_CR55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/cncr.10202","volume":"94","author":"DP Ryan","year":"2002","unstructured":"Ryan, D. P. et al. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 94, 97\u2013103 (2002).","journal-title":"Cancer"},{"key":"1029_CR56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51\u201372 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"1029_CR57","volume":"119","author":"F Meng","year":"2022","unstructured":"Meng, F. et al. A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity. Proc. Natl Acad. Sci. USA 119, e2122595119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1029_CR58","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nri2545","volume":"9","author":"DR Green","year":"2009","unstructured":"Green, D. R., Ferguson, T., Zitvogel, L. & Kroemer, G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9, 353\u2013363 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"1029_CR59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681 (2006).","journal-title":"Pharmacol. Rev."},{"key":"1029_CR60","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang, Y., Huo, M., Zhou, J. & Xie, S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Programs Biomed. 99, 306\u2013314 (2010).","journal-title":"Comput. Methods Programs Biomed."},{"key":"1029_CR61","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery. Nat. Commun. 15, 2073 (2024).","journal-title":"Nat. Commun."},{"key":"1029_CR62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0010-4655(95)00042-E","volume":"91","author":"HJC Berendsen","year":"1995","unstructured":"Berendsen, H. J. C., van der Spoel, D. & van Drunen, R. GROMACS: a message-passing parallel molecular dynamics implementation. Comput. Phys. Commun. 91, 43\u201356 (1995).","journal-title":"Comput. Phys. Commun."},{"key":"1029_CR63","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1-2","author":"MarkJames Abraham","year":"2015","unstructured":"Abraham, MarkJames et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1-2, 19\u201325 (2015).","journal-title":"SoftwareX"},{"key":"1029_CR64","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/jcc.23354","volume":"34","author":"J Huang","year":"2013","unstructured":"Huang, J. & MacKerell, A. D. Jr. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J. Comput. Chem. 34, 2135\u20133145 (2013).","journal-title":"J. Comput. Chem."},{"key":"1029_CR65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nmeth.4067","volume":"14","author":"J Huang","year":"2017","unstructured":"Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. Methods 14, 71\u201373 (2017).","journal-title":"Nat. Methods"},{"key":"1029_CR66","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1021\/ja300176w","volume":"134","author":"K Zhou","year":"2012","unstructured":"Zhou, K. et al. Multicolored pH-tunable and activatable fluorescence nanoplatform responsive to physiologic pH stimuli. J. Am. Chem. Soc. 134, 7803\u20137811 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"1029_CR67","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1007\/s00216-005-3339-5","volume":"382","author":"K Yamada","year":"2005","unstructured":"Yamada, K., Kato, N., Takagi, A., Koi, M. & Hemmi, H. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes. Anal. Bioanal. Chem. 382, 1702\u20131707 (2005).","journal-title":"Anal. Bioanal. Chem."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01029-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01029-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01029-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:04:46Z","timestamp":1761908686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01029-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":67,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["1029"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-01029-7","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L. has applied for patents related to this technology. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}